| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 7,796 | $354.04 | $2,760,095.84 | -30.4% | +2.3% | +22.1% | |
| Sep 20, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 45,767 | $16.33 | $747,433.63 | -24.9% | +61.7% | +254.7% | |
| Sep 20, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 12,651 | $16.79 | $212,355.89 | -5.7% | +61.7% | +254.7% | |
| Sep 18, 2024 | INIS International Isotopes Inc | Grosso Christopher G | Director | Buy | 800,000 | $0.03 | $24,000.00 | +2.1% | - | - | |
| Sep 17, 2024 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.63 | President And CEO | Sell | 14,550 | $1.80 | $26,131.80 | -1.9% | +30.9% | +52.8% | |
| Sep 17, 2024 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 2,608 | $1.78 | $4,650.06 | -1.6% | +30.9% | +52.8% | |
| Sep 17, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,339 | $16.50 | $38,593.50 | -1.3% | +94.1% | +212.7% | |
| Sep 17, 2024 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 10,489 | $16.50 | $173,044.90 | -34.1% | +94.1% | +212.7% | |
| Sep 17, 2024 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 25,550 | $16.50 | $421,575.00 | -11.6% | +94.1% | +212.7% | |
| Sep 16, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 7,810 | $339.12 | $2,648,527.20 | -33.2% | +8.1% | +15.4% | |
| Sep 16, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 100,000 | $0.16 | $15,600.00 | +10.0% | - | - | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Wiley Matthew T.82 | Chief Commercial Officer | Sell | 215 | $0.69 | $148.52 | -5.1% | -36.5% | -70.8% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Rodriguez Javier87 | See Remarks | Sell | 345 | $0.69 | $238.05 | -3.6% | -36.5% | -70.8% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | See Remarks | Sell | 138 | $0.69 | $95.33 | -3.4% | -36.5% | -70.8% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 355 | $0.69 | $244.70 | -2.4% | -36.5% | -70.8% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Sell | 356 | $0.69 | $245.60 | -5.4% | -36.5% | -70.8% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO And President | Sell | 1,982 | $0.69 | $1,366.91 | -1.9% | -36.5% | -70.8% | |
| Sep 13, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 250 | $56.82 | $14,205.00 | -0.4% | -3.3% | +67.0% | |
| Sep 13, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | Senior EVP, Production Center | Sell | 3,000 | $48.26 | $144,784.50 | -2.5% | -7.5% | -41.7% | |
| Sep 13, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Gemayel Georges | Director | Sell | 13,886 | $31.33 | $435,048.38 | -34.3% | +16.2% | +46.1% | |
| Sep 13, 2024 | PCRX Pacira Biosciences, Inc. | Gaugler Daryl67 | Chief Operating Officer | Sell | 500 | $12.86 | $6,430.00 | -0.4% | +51.0% | +106.9% | |
| Sep 13, 2024 | COLL Collegium Pharmaceutical, Inc | Smith Thomas B60 | EVP And Chief Medical Officer | Sell | 9,593 | $36.62 | $351,319.64 | -15.1% | -19.8% | -0.5% | |
| Sep 13, 2024 | PRGO Perrigo Co Plc | Doyle Katherine C. | Director | Sell | 8,954 | $27.30 | $244,444.20 | -59.8% | -0.6% | -19.7% | |
| Sep 13, 2024 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 3,461 | $121.88 | $421,828.06 | -67.4% | +3.7% | +16.0% | |
| Sep 12, 2024 | LQDA Liquidia Corp | Manning Paul B54 | Director | Buy | 337,078 | $8.90 | $2,999,994.20 | +70.3% | +12.6% | +167.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.